Love, Tiffany
Shabalin, Andrey A.
Kember, Rachel L. http://orcid.org/0000-0001-8820-2659
Docherty, Anna R.
Zhou, Hang http://orcid.org/0000-0002-7694-6391
Koppelmans, Vincent http://orcid.org/0000-0003-2036-7603
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Baker, Anne K. http://orcid.org/0000-0003-0127-5455
Hartwell, Emily http://orcid.org/0000-0002-5137-9714
Dubroff, Jacob
Zubieta, Jon-Kar
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (AA028292, AA028292)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (K23 DA038726, R01 DA022520, R01 DA027494, DA022520, DA027494, DA046345, DA038726)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH086858, R21 MH069612, MH069612)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health (R01 AT001415, AT001415)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities (MH086858)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Veterans Affairs (I01 CX001734, VISN 4 MIRECC)
Article History
Received: 31 October 2021
Revised: 30 March 2022
Accepted: 6 April 2022
First Online: 11 May 2022
Competing interests
: HRK is a scientific advisory board member for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant for Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative (ACTIVE Group), which over the past three years was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. HRK and JG hold US patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” 26 Jan. 2021. The other authors have no interests to disclose.